Diogo Cordeiro de Queiroz Soares
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Diogo Cordeiro de Queiroz Soares has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Chong Ae Kim
Clinical Genetics Unit, Instituto da Crianca, Hospital das Clinicas HC-FMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
11 shared publications - Maria Isabel Melaragno
Department of Morphology and Genetics, Universidade Federal de São Paulo, São Paulo, Brazil
5 shared publications - Anelisa Gollo Dantas
Genetics Division, Department of Morphology and Genetics, Universidade Federal de São Paulo, São Paulo, Brazil
4 shared publications - Leslie Domenici Kulikowski
Cytogenomics Laboratory, Departament of Pathology, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo 01246-903, Brazil
4 shared publications - Caio Robledo D' Angioli Costa Quaio
Hospital Israelita Albert Einstein, São Paulo, Brazil
3 shared publications - Claudia Berlim de Mello
Department of Psychobiology, Universidade Federal de São Paulo, São Paulo 04724-000, SP, Brazil
3 shared publications
Latest Publications
- Open Access
Neuropsychological Profile of 25 Brazilian Patients with 22q11.2 Deletion Syndrome: Effects of Clinical and Socioeconomic Variables
The 22q11.2 deletion syndrome (22q11.2DS) is associated with a heterogeneous neurocognitive phenotype, which includes psychiatric disorders. However, few studies have investigated the influence of socioeconomic variables on intellectual variability. The aim of this study was to investigate the cognitive profile of 25 patients, aged 7 to 32 years, with a typical ≈3 Mb 22q11.2 deletion, considering intellectual, adaptive, and neuropsychological functioning. Univariate linear regression analysis explored the influence of socioeconomic variables on intellectual quotient (IQ) and global adaptive behavior. Associations with relevant clinical conditions such as seizures, recurrent infections, and heart diseases were also considered. Results showed IQ scores ranging from 42 to 104. Communication, executive functions, attention, and visuoconstructive skills were the most impaired in the sample. The study found effects of access to quality education, family socioeconomic status (SES), and caregiver education level on IQ. Conversely, age at diagnosis and language delay were associated with outcomes in adaptive behavior. This characterization may be useful for better understanding the influence of social-environmental factors on the development of patients with 22q11.2 deletion syndrome, as well as for intervention processes aimed at improving their quality of life.
Open AccessNeuropsychological Profile of 25 Brazilian Patients with 22q11.2 Deletion Syndrome: Effects of Clinical and Socioeconomic Variables
The 22q11.2 deletion syndrome (22q11.2DS) is associated with a heterogeneous neurocognitive phenotype, which includes psychiatric disorders. However, few studies have investigated the influence of socioeconomic variables on intellectual variability. The aim of this study was to investigate the cognitive profile of 25 patients, aged 7 to 32 years, with a typical ≈3 Mb 22q11.2 deletion, considering intellectual, adaptive, and neuropsychological functioning. Univariate linear regression analysis explored the influence of socioeconomic variables on intellectual quotient (IQ) and global adaptive behavior. Associations with relevant clinical conditions such as seizures, recurrent infections, and heart diseases were also considered. Results showed IQ scores ranging from 42 to 104. Communication, executive functions, attention, and visuoconstructive skills were the most impaired in the sample. The study found effects of access to quality education, family socioeconomic status (SES), and caregiver education level on IQ. Conversely, age at diagnosis and language delay were associated with outcomes in adaptive behavior. This characterization may be useful for better understanding the influence of social-environmental factors on the development of patients with 22q11.2 deletion syndrome, as well as for intervention processes aimed at improving their quality of life.
- Open Access
- 30 March 2024
- Published by Wiley in Genetics Research
- Vol. 2024, 1-9
Variants in Candidate Genes for Phenotype Heterogeneity in Patients with the 22q11.2 Deletion Syndrome
22q11.2 deletion syndrome (22q11.2DS) is a microdeletion syndrome with a broad and heterogeneous phenotype, even though most of the deletions present similar sizes, involving 3Mb of DNA. In a relatively large population of a Brazilian 22q11.2DS cohort (60 patients), we investigated genetic variants that could act as genetic modifiers and contribute to the phenotypic heterogeneity, using a targeted NGS (Next Generation Sequencing) with a specific Ion AmpliSeq panel to sequence nine candidate genes (CRKL, MAPK1, HIRA, TANGO2, PI4KA, HDAC1, ZDHHC8, ZFPM2, and JAM3), mapped in and outside the 22q11.2 hemizygous deleted region. In silico prediction was performed, and the whole-genome sequencing annotation analysis package (WGSA) was used to predict the possible pathogenic effect of single nucleotide variants (SNVs). For the in silico prediction of the indels, we used the genomic variants filtered by a deep learning model in NGS (GARFIELD-NGS). We identified six variants, 4 SNVs and 2 indels, in MAPK1, JAM3, and ZFPM2 genes with possibly synergistic deleterious effects in the context of the 22q11.2 deletion. Our results provide the opportunity for the discovery of the co-occurrence of genetic variants with 22q11.2 deletions, which may influence the patients´ phenotype.
- 30 March 2024
- Published by Wiley in Genetics Research
- Vol. 2024, 1-9
Open AccessVariants in Candidate Genes for Phenotype Heterogeneity in Patients with the 22q11.2 Deletion Syndrome
22q11.2 deletion syndrome (22q11.2DS) is a microdeletion syndrome with a broad and heterogeneous phenotype, even though most of the deletions present similar sizes, involving 3Mb of DNA. In a relatively large population of a Brazilian 22q11.2DS cohort (60 patients), we investigated genetic variants that could act as genetic modifiers and contribute to the phenotypic heterogeneity, using a targeted NGS (Next Generation Sequencing) with a specific Ion AmpliSeq panel to sequence nine candidate genes (CRKL, MAPK1, HIRA, TANGO2, PI4KA, HDAC1, ZDHHC8, ZFPM2, and JAM3), mapped in and outside the 22q11.2 hemizygous deleted region. In silico prediction was performed, and the whole-genome sequencing annotation analysis package (WGSA) was used to predict the possible pathogenic effect of single nucleotide variants (SNVs). For the in silico prediction of the indels, we used the genomic variants filtered by a deep learning model in NGS (GARFIELD-NGS). We identified six variants, 4 SNVs and 2 indels, in MAPK1, JAM3, and ZFPM2 genes with possibly synergistic deleterious effects in the context of the 22q11.2 deletion. Our results provide the opportunity for the discovery of the co-occurrence of genetic variants with 22q11.2 deletions, which may influence the patients´ phenotype.
- Open Access
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 70 (suppl 1) , e2024S117
Importance of genetic cancer risk assessment as a strategy to stratify risk and provide precision prevention in high-risk patients and families
Approximately 704,000 new cases of cancer are expected to occur per year in Brazil between 2023 and 2025, corresponding to an incidence of 222 per 100,000 in men and 186 per 100,000 in women. Data from the last decades show that an epidemiological transition is occurring and cancer will soon be the first cause of death by disease in Brazil1 1 Instituto Nacional de Câncer (INCA). Estimativa 2023: incidência de câncer no Brasil / Instituto Nacional de Câncer. Rio de Janeiro (RJ): INCA; 2022a. p. 160. ,2 2 Instituto Nacional de Câncer (INCA). A situação do câncer no Brasil/Ministério da Saúde, Secretaria de Atenção à Saúde, Instituto Nacional de Câncer, Coordenação de Prevenção e Vigilância. Rio de Janeiro (RJ): INCA; 2006. p. 120. , overtaking cardiovascular diseases. Consequently, it is estimated that the annual cost of cancer treatment in the Brazilian public health system (SUS) will practically double until 2040, reaching R$ 7.8 billion3 3 Instituto Nacional de Câncer (INCA). Gastos federais atuais e futuros com os cânceres atribuíveis aos fatores de risco relacionados à alimentação, nutrição e atividade física no Brasil. Rio de Janeiro (RJ): INCA; 2022b. p. 50. . Therefore, cancer prevention and early detection are key strategies to lower incidence, mortality growth, and costs of cancer care in the public health system. Although most cancers are associated with environmental causes, approximately 5–10% are mainly due to hereditary predisposition, characterized by multiple cases in a family, early age of onset, and frequently, diagnosis of multiple primary cancers in one person. Hereditary syndromes have been well-established for the most common solid tumors such as breast and colorectal cancers. However, recent expansion of genetic testing has identified hereditary versions of practically all types of cancers, associated or not with specific phenotypic criteria. In Brazil, several studies carried out in the last decades characterized the prevalence of germline pathogenic genetic variants associated with distinct cancer types including breast, colorectal, retinoblastoma, adrenocortical carcinoma, and ovarian cancers4 4 Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty AR, et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA. 2001;98(16):9330-5. https://doi.org/10.1073/pnas.161479898 https://doi.org/10.1073/pnas.161479898... 5 Giacomazzi J, Graudenz MS, Osorio CA, Koehler-Santos P, Palmero EI, Zagonel-Oliveira M, et al. Prevalence of the TP53 p.R337H mutation in breast cancer patients in Brazil. PLoS One. 2014;9(6):e99893. https://doi.org/10.1371/journal.pone.0099893 https://doi.org/10.1371/journal.pone.009... 6 Palmero EI, Carraro DM, Alemar B, Moreira MAM, Ribeiro-Dos-Santos Â, Abe-Sandes K, et al. The germline mutational landscape of BRCA1 and BRCA2 in Brazil. Sci Rep. 2018;8(1):9188. https://doi.org/10.1038/s41598-018-27315-2 https://doi.org/10.1038/s41598-018-27315... 7 Paula AE, Galvão HCR, Bonatelli M, Sabato C, Fernandes GC, Berardinelli GN, et al. Clinicopathological and molecular characterization of Brazilian families at risk for lynch syndrome. Cancer Genet. 2021;254-5:82-91. https://doi.org/10.1016/j.cancergen.2021.02.003 https://doi.org/10.1016/j.cancergen.2021... -8 8 Guindalini RSC, Viana DV, Kitajima JPFW, Rocha VM, López RVM, Zheng Y, et al. Detection of germline variants in Brazilian breast cancer patients using multigene panel testing. Sci Rep. 2022;12(1):4190. https://doi.org/10.1038/s41598-022-07383-1 https://doi.org/10.1038/s41598-022-07383... . These studies showed a high prevalence of specific mutations also found in other populations as well as variants mostly or only observed in the Brazilian population9 9 Achatz MI, Zambetti GP. The inherited p53 mutation in the Brazilian population. Cold Spring Harb Perspect Med. 2016;6(12):a026195. https://doi.org/10.1101/cshperspect.a026195 https://doi.org/10.1101/cshperspect.a026... and contributed to the growth of scientific knowledge in the field. They also helped insert oncogenetics and genetic cancer risk assessment (GCRA) in public and private health services and established in 2009 a network funded by the Brazilian National Council for Scientific and Technological Development (CNPq) and coordinated by the Brazilian National Cancer Institute (INCA) (Rede Nacional de Cancer Familial)10 10 Instituto Nacional de Câncer (INCA). Rede nacional de câncer familial: manual operacional / Instituto Nacional de Câncer – Rio de Janeiro (RJ): INCA; 2009. p. 229. ,11 11 Ashton-Prolla P, Seuanez HN. The Brazilian hereditary cancer network: historical aspects and challenges for clinical cancer genetics in the public health care system in Brazil. Genet Mol Biol. 2016;39(2):163-5. https://doi.org/10.1590/1678-4685-GMB-2014-0373 https://doi.org/10.1590/1678-4685-GMB-20... . This network is now an autonomous organization (www.rebrach.org.br) intended to promote actions to optimize access, health care assistance, training of health care professionals, and scientific investigations in hereditary cancer.
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 70 (suppl 1) , e2024S117
Open AccessImportance of genetic cancer risk assessment as a strategy to stratify risk and provide precision prevention in high-risk patients and families
Approximately 704,000 new cases of cancer are expected to occur per year in Brazil between 2023 and 2025, corresponding to an incidence of 222 per 100,000 in men and 186 per 100,000 in women. Data from the last decades show that an epidemiological transition is occurring and cancer will soon be the first cause of death by disease in Brazil1 1 Instituto Nacional de Câncer (INCA). Estimativa 2023: incidência de câncer no Brasil / Instituto Nacional de Câncer. Rio de Janeiro (RJ): INCA; 2022a. p. 160. ,2 2 Instituto Nacional de Câncer (INCA). A situação do câncer no Brasil/Ministério da Saúde, Secretaria de Atenção à Saúde, Instituto Nacional de Câncer, Coordenação de Prevenção e Vigilância. Rio de Janeiro (RJ): INCA; 2006. p. 120. , overtaking cardiovascular diseases. Consequently, it is estimated that the annual cost of cancer treatment in the Brazilian public health system (SUS) will practically double until 2040, reaching R$ 7.8 billion3 3 Instituto Nacional de Câncer (INCA). Gastos federais atuais e futuros com os cânceres atribuíveis aos fatores de risco relacionados à alimentação, nutrição e atividade física no Brasil. Rio de Janeiro (RJ): INCA; 2022b. p. 50. . Therefore, cancer prevention and early detection are key strategies to lower incidence, mortality growth, and costs of cancer care in the public health system. Although most cancers are associated with environmental causes, approximately 5–10% are mainly due to hereditary predisposition, characterized by multiple cases in a family, early age of onset, and frequently, diagnosis of multiple primary cancers in one person. Hereditary syndromes have been well-established for the most common solid tumors such as breast and colorectal cancers. However, recent expansion of genetic testing has identified hereditary versions of practically all types of cancers, associated or not with specific phenotypic criteria. In Brazil, several studies carried out in the last decades characterized the prevalence of germline pathogenic genetic variants associated with distinct cancer types including breast, colorectal, retinoblastoma, adrenocortical carcinoma, and ovarian cancers4 4 Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty AR, et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA. 2001;98(16):9330-5. https://doi.org/10.1073/pnas.161479898 https://doi.org/10.1073/pnas.161479898... 5 Giacomazzi J, Graudenz MS, Osorio CA, Koehler-Santos P, Palmero EI, Zagonel-Oliveira M, et al. Prevalence of the TP53 p.R337H mutation in breast cancer patients in Brazil. PLoS One. 2014;9(6):e99893. https://doi.org/10.1371/journal.pone.0099893 https://doi.org/10.1371/journal.pone.009... 6 Palmero EI, Carraro DM, Alemar B, Moreira MAM, Ribeiro-Dos-Santos Â, Abe-Sandes K, et al. The germline mutational landscape of BRCA1 and BRCA2 in Brazil. Sci Rep. 2018;8(1):9188. https://doi.org/10.1038/s41598-018-27315-2 https://doi.org/10.1038/s41598-018-27315... 7 Paula AE, Galvão HCR, Bonatelli M, Sabato C, Fernandes GC, Berardinelli GN, et al. Clinicopathological and molecular characterization of Brazilian families at risk for lynch syndrome. Cancer Genet. 2021;254-5:82-91. https://doi.org/10.1016/j.cancergen.2021.02.003 https://doi.org/10.1016/j.cancergen.2021... -8 8 Guindalini RSC, Viana DV, Kitajima JPFW, Rocha VM, López RVM, Zheng Y, et al. Detection of germline variants in Brazilian breast cancer patients using multigene panel testing. Sci Rep. 2022;12(1):4190. https://doi.org/10.1038/s41598-022-07383-1 https://doi.org/10.1038/s41598-022-07383... . These studies showed a high prevalence of specific mutations also found in other populations as well as variants mostly or only observed in the Brazilian population9 9 Achatz MI, Zambetti GP. The inherited p53 mutation in the Brazilian population. Cold Spring Harb Perspect Med. 2016;6(12):a026195. https://doi.org/10.1101/cshperspect.a026195 https://doi.org/10.1101/cshperspect.a026... and contributed to the growth of scientific knowledge in the field. They also helped insert oncogenetics and genetic cancer risk assessment (GCRA) in public and private health services and established in 2009 a network funded by the Brazilian National Council for Scientific and Technological Development (CNPq) and coordinated by the Brazilian National Cancer Institute (INCA) (Rede Nacional de Cancer Familial)10 10 Instituto Nacional de Câncer (INCA). Rede nacional de câncer familial: manual operacional / Instituto Nacional de Câncer – Rio de Janeiro (RJ): INCA; 2009. p. 229. ,11 11 Ashton-Prolla P, Seuanez HN. The Brazilian hereditary cancer network: historical aspects and challenges for clinical cancer genetics in the public health care system in Brazil. Genet Mol Biol. 2016;39(2):163-5. https://doi.org/10.1590/1678-4685-GMB-2014-0373 https://doi.org/10.1590/1678-4685-GMB-20... . This network is now an autonomous organization (www.rebrach.org.br) intended to promote actions to optimize access, health care assistance, training of health care professionals, and scientific investigations in hereditary cancer.
- Open Access
- 11 July 2019
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 63 (AHEAD) , 369-375
Pheochromocytoma and paraganglioma: implications of germline mutation investigation for treatment, screening, and surveillance
Key words: Pheochromocytoma; paraganglioma; germline mutation; succinate dehydrogenase complex; screening
- 11 July 2019
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 63 (AHEAD) , 369-375
Open AccessPheochromocytoma and paraganglioma: implications of germline mutation investigation for treatment, screening, and surveillance
Key words: Pheochromocytoma; paraganglioma; germline mutation; succinate dehydrogenase complex; screening
- 9 January 2019
- Published by Springer Nature in Human Genetics
- Vol. 138 (1) , 93-103
Downregulation of genes outside the deleted region in individuals with 22q11.2 deletion syndrome
The 22q11.2 deletion syndrome (22q11.2DS) is caused by recurrent hemizygous deletions of chromosome 22q11.2. The phenotype of the syndrome is complex and varies widely among individuals. Little is known about the role of the different genes located in 22q11.2, and we hypothesized that genetic risk factors lying elsewhere in the genome might contribute to the phenotype. Here, we present the whole-genome gene expression data of 11 patients with approximately 3 Mb deletions. Apart from the hemizygous genes mapped to the 22q11.2 region, the TUBA8 and GNAZ genes, neighboring the deleted interval but in normal copy number, showed altered expression. When genes mapped to other chromosomes were considered in the gene expression analysis, a genome-wide dysregulation was observed, with increased or decreased expression levels. The enriched pathways of these genes were related to immune response, a deficiency that is frequently observed in 22q11.2DS patients. We also used the hypothesis-free weighted gene co-expression network analysis (WGCNA), which revealed the co-expression gene network modules with clear connection to mechanisms associated with 22q11.2DS such as immune response and schizophrenia. These findings, combined with the traditional gene expression profile, can be used for the identification of potential pathways and genes not previously considered to be related to the 22q11.2 deletion syndrome.
- 9 January 2019
- Published by Springer Nature in Human Genetics
- Vol. 138 (1) , 93-103
Downregulation of genes outside the deleted region in individuals with 22q11.2 deletion syndrome
The 22q11.2 deletion syndrome (22q11.2DS) is caused by recurrent hemizygous deletions of chromosome 22q11.2. The phenotype of the syndrome is complex and varies widely among individuals. Little is known about the role of the different genes located in 22q11.2, and we hypothesized that genetic risk factors lying elsewhere in the genome might contribute to the phenotype. Here, we present the whole-genome gene expression data of 11 patients with approximately 3 Mb deletions. Apart from the hemizygous genes mapped to the 22q11.2 region, the TUBA8 and GNAZ genes, neighboring the deleted interval but in normal copy number, showed altered expression. When genes mapped to other chromosomes were considered in the gene expression analysis, a genome-wide dysregulation was observed, with increased or decreased expression levels. The enriched pathways of these genes were related to immune response, a deficiency that is frequently observed in 22q11.2DS patients. We also used the hypothesis-free weighted gene co-expression network analysis (WGCNA), which revealed the co-expression gene network modules with clear connection to mechanisms associated with 22q11.2DS such as immune response and schizophrenia. These findings, combined with the traditional gene expression profile, can be used for the identification of potential pathways and genes not previously considered to be related to the 22q11.2 deletion syndrome.
- Open Access
- 3 January 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-9
Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil
BRCA1/2 pathogenic (P) and likely pathogenic (LP) germline variants are frequent among patients with ovarian carcinoma. However, these variants have not been extensively characterized in patients with ovarian cancer in Brazil. In this retrospective study we evaluated clinical characteristics and BRCA1/2 genetic test results from patients with ovarian carcinoma who underwent genetic counseling at A.C.Camargo Cancer Center (Brazil) between 2015 and 2017 and had performed germline genetic testing of BRCA1/2 genes. Among 158 patients, 33 P and LP variants and were found (20.8%), 27 in BRCA1 and six in BRCA2, and six variants of unknown clinical significance (VUS). Thirteen percent of the patients did not have Multiplex Ligation-dependent Probe Amplification (MLPA) results. Three P variants in BRCA1 were found in more than one patient: c.5266dupC (p.Gln1756Profs*74), c.3331_3334delCAAG (p.Gln1111Asnfs5*), and c.211A > G (p.Arg71Gly). One LP variant in BRCA1 had not been previously described, c.4153_4154delCT (p.Leu1385Ilefs*5). Patients with previous diagnosis of breast cancer were carriers of P or LP variant in 8 of 12 cases (66.7%), and patients with a family history of ovarian or breast cancer in first- or second-degree relatives were carriers of P or LP variant in 26.7% of cases compared to 16.9% for patients without family history (p = 0.166). Prevalence of BRCA1/2 germline P and LP variants is slightly higher than previously described by the largest occidental studies, with a high prevalence of variant c.5266dupC (p.Gln1756Profs*74) in BRCA1 observed. Moreover, we identified a new LP variant.
- 3 January 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-9
Open AccessPrevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil
BRCA1/2 pathogenic (P) and likely pathogenic (LP) germline variants are frequent among patients with ovarian carcinoma. However, these variants have not been extensively characterized in patients with ovarian cancer in Brazil. In this retrospective study we evaluated clinical characteristics and BRCA1/2 genetic test results from patients with ovarian carcinoma who underwent genetic counseling at A.C.Camargo Cancer Center (Brazil) between 2015 and 2017 and had performed germline genetic testing of BRCA1/2 genes. Among 158 patients, 33 P and LP variants and were found (20.8%), 27 in BRCA1 and six in BRCA2, and six variants of unknown clinical significance (VUS). Thirteen percent of the patients did not have Multiplex Ligation-dependent Probe Amplification (MLPA) results. Three P variants in BRCA1 were found in more than one patient: c.5266dupC (p.Gln1756Profs*74), c.3331_3334delCAAG (p.Gln1111Asnfs5*), and c.211A > G (p.Arg71Gly). One LP variant in BRCA1 had not been previously described, c.4153_4154delCT (p.Leu1385Ilefs*5). Patients with previous diagnosis of breast cancer were carriers of P or LP variant in 8 of 12 cases (66.7%), and patients with a family history of ovarian or breast cancer in first- or second-degree relatives were carriers of P or LP variant in 26.7% of cases compared to 16.9% for patients without family history (p = 0.166). Prevalence of BRCA1/2 germline P and LP variants is slightly higher than previously described by the largest occidental studies, with a high prevalence of variant c.5266dupC (p.Gln1756Profs*74) in BRCA1 observed. Moreover, we identified a new LP variant.
- Open Access
- 1 January 2019
- Published by FapUNIFESP (SciELO) in Estudos de Psicologia (Campinas)
- Vol. 36
Intellectual performance profi le of a sample of children and adolescents from Brazil with 22q11.2 Deletion Syndrome (22q11.2DS) based on the Wechsler Scale
The 22q11.2 Deletion Syndrome (22q11.2DS), the most common human chromosome microdeletion syndrome, is associated with a very heterogeneous neurocognitive phenotype. One of the main characteristics of the syndrome spectrum is the intellectual variability, which encompasses average performance and intellectual disability and discrepancies between Verbal Intelligence Quotient and Performance Verbal Intelligence Quotient, with greater impairment in nonverbal tasks. The present study aimed at investigating the intellectual performance aspects of a 21children and adolescents sample from Brazil who had been diagnosed with 22q11.2DS, based on the Wechsler Intelligence Scale for Children - 4th edition. The samples were reviewed considering the differences between indices. The results revealed an Full Scale Intelligence Quotient predominant in the borderline range (42 to 104) and a significant discrepancy between the indices of Verbal Comprehension and Perceptual Reasoning in 42% of the sample. With regard to the performance in the subtests alone, a better performance was found in Similarities, whereas block design, matrix reasoning, digit span and letter-number sequencing subtests were the most challenging. These findings indicate that a comprehensive assessment of intellectual performance aspects covering the different measures of the Wechsler Intelligence Scale may contribute to a broader understanding of the neurocognitive phenotype associated with 22q11.2DS.
- 1 January 2019
- Published by FapUNIFESP (SciELO) in Estudos de Psicologia (Campinas)
- Vol. 36
Open AccessIntellectual performance profi le of a sample of children and adolescents from Brazil with 22q11.2 Deletion Syndrome (22q11.2DS) based on the Wechsler Scale
The 22q11.2 Deletion Syndrome (22q11.2DS), the most common human chromosome microdeletion syndrome, is associated with a very heterogeneous neurocognitive phenotype. One of the main characteristics of the syndrome spectrum is the intellectual variability, which encompasses average performance and intellectual disability and discrepancies between Verbal Intelligence Quotient and Performance Verbal Intelligence Quotient, with greater impairment in nonverbal tasks. The present study aimed at investigating the intellectual performance aspects of a 21children and adolescents sample from Brazil who had been diagnosed with 22q11.2DS, based on the Wechsler Intelligence Scale for Children - 4th edition. The samples were reviewed considering the differences between indices. The results revealed an Full Scale Intelligence Quotient predominant in the borderline range (42 to 104) and a significant discrepancy between the indices of Verbal Comprehension and Perceptual Reasoning in 42% of the sample. With regard to the performance in the subtests alone, a better performance was found in Similarities, whereas block design, matrix reasoning, digit span and letter-number sequencing subtests were the most challenging. These findings indicate that a comprehensive assessment of intellectual performance aspects covering the different measures of the Wechsler Intelligence Scale may contribute to a broader understanding of the neurocognitive phenotype associated with 22q11.2DS.
- 24 July 2018
- Published by Wolters Kluwer Health in Neurology
- Vol. 91 (4) , 187-190
Pearls & Oy-sters: A curable myopathy manifesting as exercise intolerance and respiratory failure
Few forms of severe genetic myopathies can successfully be treated, although multiple acyl-CoA dehydrogenase deficiency (MADD) is highly responsive to riboflavin supplementation.
- 24 July 2018
- Published by Wolters Kluwer Health in Neurology
- Vol. 91 (4) , 187-190
Pearls & Oy-sters: A curable myopathy manifesting as exercise intolerance and respiratory failure
Few forms of severe genetic myopathies can successfully be treated, although multiple acyl-CoA dehydrogenase deficiency (MADD) is highly responsive to riboflavin supplementation.
- Open Access
Natural history of 39 patients with Achondroplasia
To characterize the natural history of 39 achondroplastic patients diagnosed by clinical, radiological and molecular assessments.Observational and retrospective study of 39 patients who were attended at a public tertiary level hospital between 1995 and ...
Open AccessNatural history of 39 patients with Achondroplasia
To characterize the natural history of 39 achondroplastic patients diagnosed by clinical, radiological and molecular assessments.Observational and retrospective study of 39 patients who were attended at a public tertiary level hospital between 1995 and ...
- 1 January 2017
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in Intractable & Rare Diseases Research
- Vol. 6 (3) , 183-190
Mucopolysaccharidosis type I, II and VI and response to enzyme replacement therapy: Results from a single-center case series study
Mucopolysaccharidoses (MPS) types I, II and VI are associated with deficiencies in alpha-L-iduronidase, iduronate-2-sulfatase and N-acetylgalactosamine-4-sulfatase, respectively, and generally involve progressive and multi-systemic clinical manifestations. Enzyme replacement therapy (ERT) appears to be reasonably well tolerated. The aim of this study was to examine clinical and diagnostic findings of a series of pediatric and adult MPS patients, and assess the safety and efficacy of ERT in children and adults with MPS type I, II and VI. Pediatric and adult patients were treated weekly with 1 mg/kg recombinant human N-acetylgalactosamine-4-sulphatase (rhASB), 0.45 mg/kg alpha-L-iduronidase, or 0.5 mg/kg iduronate-2-sulfatase. Clinical and biochemical parameters with ERT were evaluated for a mean duration of 5 years. Mantel-Haenszel risk ratios and associated 95% confidence intervals (CIs) were calculated for rates of death among different types of enzyme replacement therapies (ERTs). Twenty-seven patients (mean ages ‒ pediatric: 6.8 years; adult: 29 years) were included. ERT was found to be consistently well tolerated and effective in attenuating symptoms, but did not prevent the progression of the disease or reduce mortality rates. Our findings demonstrated that early diagnosis and initiation of ERT are critical for improvements in patient-important outcomes and quality of life, although disease progression and mortality rates remain high.
- 1 January 2017
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in Intractable & Rare Diseases Research
- Vol. 6 (3) , 183-190
Mucopolysaccharidosis type I, II and VI and response to enzyme replacement therapy: Results from a single-center case series study
Mucopolysaccharidoses (MPS) types I, II and VI are associated with deficiencies in alpha-L-iduronidase, iduronate-2-sulfatase and N-acetylgalactosamine-4-sulfatase, respectively, and generally involve progressive and multi-systemic clinical manifestations. Enzyme replacement therapy (ERT) appears to be reasonably well tolerated. The aim of this study was to examine clinical and diagnostic findings of a series of pediatric and adult MPS patients, and assess the safety and efficacy of ERT in children and adults with MPS type I, II and VI. Pediatric and adult patients were treated weekly with 1 mg/kg recombinant human N-acetylgalactosamine-4-sulphatase (rhASB), 0.45 mg/kg alpha-L-iduronidase, or 0.5 mg/kg iduronate-2-sulfatase. Clinical and biochemical parameters with ERT were evaluated for a mean duration of 5 years. Mantel-Haenszel risk ratios and associated 95% confidence intervals (CIs) were calculated for rates of death among different types of enzyme replacement therapies (ERTs). Twenty-seven patients (mean ages ‒ pediatric: 6.8 years; adult: 29 years) were included. ERT was found to be consistently well tolerated and effective in attenuating symptoms, but did not prevent the progression of the disease or reduce mortality rates. Our findings demonstrated that early diagnosis and initiation of ERT are critical for improvements in patient-important outcomes and quality of life, although disease progression and mortality rates remain high.